Plerixafor 8HCl (DB06809)

Catalog No. A10913

Plerixafor 8HCl (DB06809)是CXCR4趋化因子受体拮抗剂，作用于CXCR4和CXCL12介导调节的趋化性， IC50分别为44 nM和5.7 nM。

Product Citations

Mei Zheng, .et al. CXCL12 inhibits hair growth through CXCR4, Biomed Pharmacother, 2022, Jun;150:112996 PMID: 35462338
Asiedu KO, .et al. Bone marrow cell homing to sites of acute tibial fracture: 89Zr-oxine cell labeling with positron emission tomographic imaging in a mouse model, EJNMMI Res, 2018, Dec 13;8(1):109 PMID: 30547233
Kingsley O. Asiedu, .et al. Bone marrow cell trafficking analyzed by 89Zr-oxine positron emission tomography in a murine transplantation model, Clin Cancer Res, 2017, Jun 1; 23(11): 2759-2768 PMID: 27965305

Technical details

Catalog Num	A10913
M. Wt	794.5
Formula	C28H54N8.8HCl
Purity	>98%
Storage	at -20°C 3 years Powder
CAS No.	155148-31-5
Synonyms	DB06809, AMD3100, Mozobil
SMILES	C1CNCCNCCCN(CCNC1)CC2=CC=C(C=C2)CN3CCCNCCNCCCNCC3.Cl.Cl.Cl.Cl.Cl.Cl.Cl.Cl

Biological Activity

Plerixafor 8HCl (DB06809)是CXCR4趋化因子受体拮抗剂，作用于CXCR4和CXCL12介导调节的趋化性， IC50分别为44 nM和5.7 nM。

Targets

CXCL12-mediated chemotaxis (Cell-free assay)	CXCR4 (Cell-free assay)
5.7 nM	44 nM

Solubility *

In vitro (25°C)	DMSO	Insoluble
	Water	91 mg/mL (114.54 mM)
	Ethanol	Insoluble
In vivo	Saline	28 mg/mL
* <1 mg/ml means slightly soluble or insoluble. * Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Preparing Stock Solutions

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
0.1 mM	12.59 mL	62.93 mL	125.87 mL
0.5 mM	2.52 mL	12.59 mL	25.17 mL
1 mM	1.26 mL	6.29 mL	12.59 mL
5 mM	0.25 mL	1.26 mL	2.52 mL

*The above data is based on the productmolecular weight 794.5 . Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.